Sir, Acinetobacter spp. are opportunistic pathogens with increasing relevance in nosocomial infections, especially among immunocompromised patients. Extensive use of antimicrobial chemotherapy for these infections has contributed to the emergence and increase of multidrug-resistant Acinetobacter spp., such as Acinetobacter baumannii strains, in various hospitals. Such strains frequently exhibit resistance to β-lactams, aminoglycosides and fluoroquinolones. Carbapenems usually retain good potency, with imipenem being the most active against A. baumannii. 1 However, in the last few years, carbapenem-resistant A. baumannii isolates have also been reported. 2 Such strains exhibit various levels of susceptibility and owe their resistance either to target inaccessibility or to drug inactivation by β-lactamases. We report the spread of low-level carbapenemresistant A. baumannii clones in a tertiary care university Greek hospital.
During the study period (November 2000-November 2001), 107 A. baumannii isolates were recovered consecutively from clinical infections of 107 different patients hospitalized at Hippokration University Hospital, Thessaloniki, Greece, the largest hospital in northern Greece. Isolates were recovered from blood, urine samples, bronchial secretions and wound exudates. Following the instructions of the API 20NE system (bioMérieux API, Marcy l'Étoile, France), the isolates were identified provisionally to genus species. The classification of A. baumannii was performed by a simplified identification scheme. For determination of MICs by the agar dilution method, imipenem and meropenem solutions and MIC plates were prepared freshly on the day of testing. The agar dilution technique was performed by inoculating 10 4 cfu/spot onto cationsupplemented Mueller-Hinton agar plates (BBL, Cockeysville, MD, USA) containing antibiotic dilutions in the range 0.06-64 mg/L. MIC was recorded as the lowest drug concentration at which no growth occurred. Pseudomonas aeruginosa (ATCC 27853) was used as a control and was consistently characterized as having MIC ≤ 2 mg/L for imipenem and ≤ 0.5 mg/L for meropenem.
The majority of the clinical isolates examined exhibited low-level resistance to either imipenem (55 of 107 isolates, 51.4%) or meropenem (93 of 107 isolates, 86.9%), with the MICs in the range 2-8 mg/L, compared with MICs of 0.12-0.25 mg/L for 15 historical isolates from our hospital and relative to an MIC breakpoint of 4 mg/L. In particular, imipenem and meropenem MICs of 8 mg/L were detected for 15 and three isolates, of 4 mg/L for 11 and 28 isolates, and of 2 mg/L for 29 and 62 isolates, respectively (Table 1) . Among all these isolates, cross-resistance to penicillins, penicillins with β-lactam inhibitors, cephalosporins, aminoglycosides and quinolones was virtually complete.
PCR testing of the 93 low-level imipenem-or meropenemresistant isolates for carbapenemase genes (bla IMP , bla VIM , bla OXA-23-like and bla OXA-24-like ) was carried out using specific primers. The genes were not detected in any isolate. The isolates were also tested phenotypically, by Etest MBL (AB Biodisk, Solna, Sweden), for the possible production of a metallo-β-lactamase; the test was negative in all cases. Pulsed-field gel electrophoresis of ApaI-digested genomic DNA was performed and banding patterns were compared visually. Nine distinct clones were defined, each containing 3-21 isolates. It is of interest that all but three of the 15 isolates that exhibited an MIC of imipenem of 8 mg/L were indistinguishable, indicating a clonal spread of these acinetobacters. This particular clone was not defined among the remaining low-level carbapenem-resistant isolates or among those that were fully susceptible. Carbapenem-resistant acinetobacters have been reported sporadically from clinical infections after prolonged exposure to carbapenems. 2 However, the emergence of strains that exhibit low-level resistance to carbapenems is limited. In a UK burns unit, acinetobacters that exhibit MICs of 2 and 0.5 mg/L of meropenem and imipenem, respectively, have been reported. 3 In addition, a USA electronic surveillance programme has recorded a yearly increase in A. baumanni strains with reduced susceptibility to imipenem. 4 In our region, acinetobacters are one of the most frequent nosocomial pathogens, and the majority of them are multidrug-resistant, leading to an extensive use of carbapenems. 5 The detection in one of the largest Greek hospitals that the vast majority of A. baumannii exhibit low-level resistance to carbapenems is a novel observation, suggesting a potential for wider dissemination. Since the disc diffusion method is not always sensitive in the detection of strains with lowlevel resistance to carbapenems, 3 it is important that our diagnostic laboratories use a reference susceptibility method to screen periodically for the presence of such acinetobacters. The continuing spread of low-level carbapenem-resistant A. baumannii clones in our hospital demands more prudent use of antimicrobials and more strict infection control measures. Further studies, to determine if similar clones exist in other hospitals, are important in continuing to monitor this situation.
Sir, The time above the minimum inhibitory concentration (t > MIC) is considered to best predict the in vivo activity of β-lactam antibacterial agents, with administration by continuous infusion (CI) allowing optimization of the t > MIC over a 24 h period. 1 Preclinical and clinical evidence indicates that the drug concentration in serum should reach 4-5 times the MIC value to exert the maximum bactericidal effect during CI. 1,2 However, such a value may be hard to reach in infections caused by difficult to treat Gram-negative bacteria, like Pseudomonas aeruginosa. Ceftazidime is one of the more extensively studied drugs that are currently given by CI administration and its clinical efficacy has been confirmed in different patient populations. [3] [4] [5] The in vitro study we report here was undertaken to assess the bactericidal activity of different ceftazidime concentrations on either susceptible or resistant P. aeruginosa isolates. All of the study strains were obtained from respiratory samples from patients hospitalized in intensive care units. Six of the P. aeruginosa strains were susceptible (CTZ-S) with MIC values ≤ 8 mg/L; four strains were intermediate (MIC = 16 mg/L; CTZ-I) and three strains were resistant (CTZ-R) with MIC values ≥ 32 mg/L. MIC values were determined for each of the study strains by the NCCLS methodology. 6 Bactericidal activity was defined as a ≥3 log 10 reduction in a 10 5 cfu/mL inoculum. Bacterial suspensions were prepared from an overnight agar plate culture, then transferred into Mueller-Hinton broth supplemented with calcium (25 mg/L) and magnesium (12.5 mg/L) and incubated for 2 h at 37°C to reach logarithmic phase. Ceftazidime concentrations of 2 ×, 4 × and 8 × MIC as exact multiples of the MIC value were added to the medium and bacterial counts carried out after 0, 4, 6, 8 and 24 h. In order to avoid ceftazidime carryover, 0.1 mL aliquots were sampled with a detection limit of 10 cfu/mL. All the experiments were repeated two times.
Ceftazidime exerted maximal bactericidal activity within 6-8 h in all the experiments (Figure 1 ). Eleven out of 13 strains and 12 out of 13 strains, exposed to 4 × and 8 × MIC, respectively, showed a decrease of more than 3 log 10 cfu/mL at 6 h after antibiotic exposure.
In the experiments where the strains were exposed to 2 × MIC, a decrease of 2.4-4.8 log 10 cfu/mL was observed after 6-8 h of antibiotic exposure, even though four (MIC range 4-32 mg/L) out of 13 strains showed re-growth after 24 h. No variations in the bac-
